NewAmsterdam Pharma (NASDAQ:NAMS) Receives "Sell (D-)" Rating from Weiss Ratings

NewAmsterdam Pharma (NASDAQ:NAMS - Get Free Report)'s stock had its "sell (d-)" rating restated by analysts at Weiss Ratings in a research note issued to investors on Saturday,Weiss Ratings reports.

Other analysts have also issued reports about the company. Royal Bank Of Canada lifted their price target on NewAmsterdam Pharma from $38.00 to $39.00 and gave the stock an "outperform" rating in a report on Thursday, August 7th. Wall Street Zen upgraded NewAmsterdam Pharma from a "sell" rating to a "hold" rating in a research note on Saturday, July 5th. Citigroup boosted their target price on NewAmsterdam Pharma from $42.00 to $50.00 and gave the company a "buy" rating in a research note on Friday, October 17th. HC Wainwright began coverage on NewAmsterdam Pharma in a research note on Monday, October 20th. They issued a "buy" rating and a $52.00 target price on the stock. Finally, The Goldman Sachs Group began coverage on NewAmsterdam Pharma in a research report on Thursday, July 17th. They issued a "neutral" rating and a $27.00 price target for the company. Eight equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, NewAmsterdam Pharma currently has a consensus rating of "Moderate Buy" and a consensus target price of $43.20.

NewAmsterdam Pharma Stock Down 1.5%

NAMS stock opened at $35.72 on Friday. NewAmsterdam Pharma has a twelve month low of $14.06 and a twelve month high of $41.47. The stock's 50 day moving average is $28.94 and its 200-day moving average is $22.94. The firm has a market capitalization of $4.02 billion, a PE ratio of -22.05 and a beta of 0.02.

NewAmsterdam Pharma (NASDAQ:NAMS - Get Free Report) last posted its earnings results on Wednesday, August 6th. The company reported ($0.15) earnings per share for the quarter, beating analysts' consensus estimates of ($0.52) by $0.37. NewAmsterdam Pharma had a negative return on equity of 27.27% and a negative net margin of 259.07%.The company had revenue of $19.15 million for the quarter, compared to analyst estimates of $1.44 million. On average, equities research analysts anticipate that NewAmsterdam Pharma will post -1.75 earnings per share for the current fiscal year.

Insider Activity

In other NewAmsterdam Pharma news, Director James N. Topper purchased 1,260 shares of the stock in a transaction on Monday, September 8th. The stock was acquired at an average price of $24.99 per share, with a total value of $31,487.40. Following the transaction, the director directly owned 3,027,864 shares of the company's stock, valued at approximately $75,666,321.36. This trade represents a 0.04% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, CAO Louise Frederika Kooij sold 150,000 shares of the company's stock in a transaction that occurred on Tuesday, September 9th. The shares were sold at an average price of $25.83, for a total value of $3,874,500.00. Following the transaction, the chief accounting officer directly owned 15,000 shares of the company's stock, valued at $387,450. The trade was a 90.91% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders purchased 2,391 shares of company stock valued at $58,424 and sold 226,342 shares valued at $5,748,019. 20.84% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in NAMS. Mather Group LLC. purchased a new stake in NewAmsterdam Pharma during the 3rd quarter valued at $28,000. Thurston Springer Miller Herd & Titak Inc. purchased a new position in NewAmsterdam Pharma in the third quarter worth about $30,000. Quarry LP bought a new stake in NewAmsterdam Pharma in the first quarter worth about $25,000. Mirae Asset Global Investments Co. Ltd. boosted its holdings in shares of NewAmsterdam Pharma by 19.4% in the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,675 shares of the company's stock valued at $80,000 after purchasing an additional 596 shares during the period. Finally, Zurcher Kantonalbank Zurich Cantonalbank raised its stake in NewAmsterdam Pharma by 130.4% in the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,990 shares of the company's stock worth $123,000 after buying an additional 3,390 shares in the last quarter. Hedge funds and other institutional investors own 89.89% of the company's stock.

NewAmsterdam Pharma Company Profile

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.